{"protocolSection":{"identificationModule":{"nctId":"NCT00630331","orgStudyIdInfo":{"id":"V58P13"},"secondaryIdInfos":[{"id":"2007-002871-15"},{"id":"11580"}],"organization":{"fullName":"Novartis","class":"INDUSTRY"},"briefTitle":"Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects","officialTitle":"A Phase III, Randomized, Observer-Blind, Placebo-Controlled, Multicenter Study to Assess Clinical Efficacy of a Cell-Derived Subunit Influenza Vaccine and an Egg-Derived Subunit Influenza Vaccine in the 2007-2008 Influenza Season in Healthy Adult Subjects"},"statusModule":{"statusVerifiedDate":"2024-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-10"},"primaryCompletionDateStruct":{"date":"2008-07","type":"ACTUAL"},"completionDateStruct":{"date":"2008-07","type":"ACTUAL"},"studyFirstSubmitDate":"2008-02-28","studyFirstSubmitQcDate":"2008-03-06","studyFirstPostDateStruct":{"date":"2008-03-07","type":"ESTIMATED"},"resultsFirstSubmitDate":"2012-11-21","resultsFirstSubmitQcDate":"2013-01-15","resultsFirstPostDateStruct":{"date":"2013-01-16","type":"ESTIMATED"},"dispFirstSubmitDate":"2011-03-16","dispFirstSubmitQcDate":"2011-03-16","dispFirstPostDateStruct":{"date":"2011-03-28","type":"ESTIMATED"},"lastUpdateSubmitDate":"2024-05-22","lastUpdatePostDateStruct":{"date":"2024-05-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Novartis Vaccines","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"The present study will evaluate clinical efficacy, safety, tolerability and immunogenicity of both Novartis Vaccines' cell-derived influenza vaccine and egg-derived influenza vaccine in healthy adults 18 to 49 years of age."},"conditionsModule":{"conditions":["Influenza"],"keywords":["Influenza","Flu","Cell Culture-Derived","Egg-Derived","Healthy Adults","Efficacy","Safety","Immunogenicity","Trivalent","Inactivated","Influenza-Like Illness","Vaccination"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"SINGLE","whoMasked":["PARTICIPANT"]}},"enrollmentInfo":{"count":11404,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"CCI","type":"EXPERIMENTAL","description":"Subjects received one dose of cell culture-derived influenza vaccine.","interventionNames":["Biological: Cell culture-derived influenza vaccine"]},{"label":"IVV","type":"EXPERIMENTAL","description":"Subjects received one dose of the trivalent egg-derived influenza vaccine.","interventionNames":["Biological: Egg-derived influenza virus vaccine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Subjects received one dose of phosphate buffered solution (PBS).","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Cell culture-derived influenza vaccine","description":"One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle.","armGroupLabels":["CCI"]},{"type":"BIOLOGICAL","name":"Egg-derived influenza virus vaccine","description":"One dose (0.5 mL) of the trivalent egg-derived influenza virus vaccine, administered in the deltoid muscle.","armGroupLabels":["IVV"]},{"type":"BIOLOGICAL","name":"Placebo","description":"One dose (0.5 mL) of phosphate buffered solution.","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Subjects With Culture-Confirmed Influenza Illness Caused by Vaccine-like Strains","description":"The vaccine efficacy of CCI and IVV vaccines was estimated relative to Placebo group as the number of subjects prevented against virus-confirmed symptomatic influenza illness caused by each of three vaccine-like virus strains.","timeFrame":"6 Months"}],"secondaryOutcomes":[{"measure":"Number of Subjects With Culture-confirmed Influenza Illness Caused by Non-Vaccine Like Strains","description":"The vaccine efficacy of CCI and IVV vaccines was estimated relative to placebo group as the number of subjects prevented against virus-confirmed symptomatic influenza A or B illness caused by non-vaccine-like strains.","timeFrame":"6 Months"},{"measure":"Number of Subjects With Influenza Caused by Vaccine-like and Non-vaccine-like Strains","description":"The vaccine efficacy of CCI and IVV vaccines was estimated relative to placebo as the number of subjected prevented against virus-confirmed symptomatic influenza A or B illness caused by vaccine-like and non-vaccine-like strains.","timeFrame":"6 Months"},{"measure":"Influenza-Associated Days in Bed, All Subjects","description":"The number of subjects in this analysis included all subjects in the per protocol efficacy population.","timeFrame":"6 Months"},{"measure":"Influenza-Associated Days in Bed, Subset of Subjects With Virus-Confirmed- Influenza","description":"The analysis was done among the subset of subjects in the per protocol efficacy population who had culture-confirmed influenza.","timeFrame":"6 Months"},{"measure":"Number Of Medical Visits (Inpatient and Outpatient) Due to Influenza Illness or Symptoms of Influenza, All Subjects","description":"The number of subjects in this analysis included all subjects in the per protocol efficacy population.","timeFrame":"6 Months"},{"measure":"Number of Medical Visits (Inpatient and Outpatient), Subset of Subjects With Virus-Confirmed-Influenza","description":"The analysis was done among the subset of subjects in the per protocol efficacy population who had culture-confirmed influenza.","timeFrame":"6 Months"},{"measure":"Number of Days of Usual Activity (i.e. Job, School,Household/Family/Community Activities) Lost Due to Influenza Disease, All Subjects","description":"The number of subjects in this analysis included all subjects in the per protocol efficacy population.","timeFrame":"6 Months"},{"measure":"Number of Days of Usual Activity (i.e. Job, School,Household/Family/Community Activities) Lost, Subset of Subjects With Virus-Confirmed-Influenza","description":"The analysis was done among the subset of subjects in the per protocol efficacy population who had culture-confirmed influenza.","timeFrame":"6 Months"},{"measure":"Percentages of Subjects Who Achieved HI Titers ≥40 After One Vaccination of Either Cell-culture Derived or Egg-derived Influenza Vaccine or Placebo","description":"Immunogenicity was measured as the percentage of subjects achieving HI titers ≥40 at baseline (day 1) and three weeks after (day 22) one vaccination of either cell-culture or egg-derived vaccine or placebo for each of the three influenza vaccine strains (A/H1N1, A/H3N2 and B), evaluated using hemagglutination inhibition (HI) egg-derived antigen assay. This criterion is met according to US (CBER) guideline if the lower limit of the two-sided 95% CI for the percentage of subjects achieving HI titers ≥40 is ≥70%.","timeFrame":"Before vaccination (day 1) and three weeks after vaccination (day 22)"},{"measure":"Percentages of Subjects Achieving Seroconversion After One Vaccination of Either Cell-culture Derived or Egg-derived Influenza Vaccine or Placebo","description":"As per the CBER guideline, seroconversion is defined as the percentage of subjects with a prevaccination HI titer \\<10, a postvaccination titer ≥40; or in subjects with prevaccination HI titer ≥10, a ≥4-fold increase in postvaccination HI antibody titer. According to CBER criteria, the lower limit of the two-sided 95% CI for the percentage of subjects achieving seroconversion for HI antibody titer at day 22 met exceeded 40%.","timeFrame":"Three weeks after vaccination (day 22)"},{"measure":"Number of Subjects Reported Solicited Local and Systemic Reactions up to 7 Days After Vaccination","description":"The solicited local and systemic reactogenicity were collected up to 7 days after vaccination for all three vaccine groups.","timeFrame":"Up to 7 days post vaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. subjects 18 to 49 years of age;\n2. in good health as determined by medical history and physical examination;\n3. able and willing to provide written informed consent prior to any study procedure;\n4. able to comply with all study procedures, including availability and willingness to be actively followed throughout the ensuing influenza season with weekly telephone calls and to comply with the need for prompt collection of nasal and throat specimens in the event of influenza symptoms.\n\nExclusion Criteria:\n\n1. history of anaphylaxis or serious reaction after administration of any vaccine, or hypersensitivity to eggs, egg protein, chicken feathers, influenza viral protein, neomycin, kanamycin, or any other vaccine component, chemically related substance, or component of the potential packaging materials;\n2. any health condition for which the inactivated vaccine is recommended by the Advisory Committee on Immunization Practices (ACIP) including chronic diseases of the pulmonary or cardiovascular systems (including asthma), chronic metabolic diseases (including diabetes), renal dysfunction, hemoglobinopathies, immune deficiency disease (including HIV infection) or on-going immunosuppressive therapy;\n3. employment in professions prone to influenza transmission to or from high-risk populations (this exclusion specifically includes nurses, physicians, all other healthcare workers with direct patient contact; and police, fire, and rescue personnel); or living in the same household as an immunocompromised person;\n4. history of Guillain-Barré syndrome;\n5. bleeding diathesis;\n6. receipt of another investigational agent within 90 days prior to enrollment in the study or before completion of the safety follow-up period in another study, whichever is longer, and unwilling to refuse participation in another clinical study through the end of the study;\n7. receipt of another vaccine within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to Visit 1;\n8. laboratory-confirmed influenza disease within 6 months prior to Visit 1;\n9. receipt of an influenza vaccine within 6 months prior to Visit 1 or plans to receive influenza vaccine outside of this study;\n10. experienced a temperature (≥100.0°F / ≥37.8°C) and/or any acute illness within 3 days prior to study vaccination;\n11. pregnant or breast-feeding female;\n12. if female of childbearing potential and sexually active, has not used any of the birth control methods detailed in the section entitled \"Females of Childbearing Potential\" for at least 2 months prior to study entry;\n13. if female of childbearing potential and sexually active, refusal to use a reliable contraceptive method as detailed in the section entitled \"Females of Childbearing Potential\" during the first 3 weeks after vaccination;\n14. research staff directly involved with the clinical study or family members or household members of research staff. Research staff are individuals with direct or indirect contact with study subjects, or study site personnel who have access to any study documents containing subject information. This would include receptionists, persons scheduling appointments or making screening calls, regulatory specialists, laboratory technicians, etc.;\n15. any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives or with the safety of the study subject.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"49 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Novartis Vaccines","affiliation":"Novartis Vaccines","role":"STUDY_CHAIR"}],"locations":[{"facility":"Site 14","city":"Denver","state":"Colorado","zip":"80212","country":"United States","geoPoint":{"lat":39.73915,"lon":-104.9847}},{"facility":"Site 15","city":"Pembroke Pines","state":"Florida","zip":"33024","country":"United States","geoPoint":{"lat":26.00315,"lon":-80.22394}},{"facility":"Site 17","city":"South Miami","state":"Florida","zip":"33143","country":"United States","geoPoint":{"lat":25.7076,"lon":-80.29338}},{"facility":"Site 13","city":"Lenexa","state":"Kansas","zip":"66219","country":"United States","geoPoint":{"lat":38.95362,"lon":-94.73357}},{"facility":"Site 2","city":"Bardstown","state":"Kentucky","zip":"40004","country":"United States","geoPoint":{"lat":37.80923,"lon":-85.4669}},{"facility":"Site 1","city":"St Louis","state":"Missouri","zip":"63140","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Site 4","city":"Edison","state":"New Jersey","zip":"08817","country":"United States","geoPoint":{"lat":40.51872,"lon":-74.4121}},{"facility":"Site 10","city":"Binghamton","state":"New York","zip":"13901","country":"United States","geoPoint":{"lat":42.09869,"lon":-75.91797}},{"facility":"Site 5","city":"Endwell","state":"New York","zip":"13760","country":"United States","geoPoint":{"lat":42.11285,"lon":-76.02103}},{"facility":"Site 16","city":"Winston-Salem","state":"North Carolina","zip":"27103","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"Site 11","city":"Warwick","state":"Rhode Island","zip":"02886","country":"United States","geoPoint":{"lat":41.7001,"lon":-71.41617}},{"facility":"Site 12","city":"Anderson","state":"South Carolina","zip":"29621","country":"United States","geoPoint":{"lat":34.50344,"lon":-82.65013}},{"facility":"Site 9","city":"Austin","state":"Texas","zip":"78705","country":"United States","geoPoint":{"lat":30.26715,"lon":-97.74306}},{"facility":"Site 8","city":"Dallas","state":"Texas","zip":"75234","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Site 7","city":"Salt Lake City","state":"Utah","zip":"84109","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Site 3","city":"Salt Lake City","state":"Utah","zip":"84121","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"Site 6","city":"Burke","state":"Virginia","zip":"22105","country":"United States","geoPoint":{"lat":38.79345,"lon":-77.27165}},{"facility":"Site 25","city":"Espoo","zip":"02100","country":"Finland","geoPoint":{"lat":60.2052,"lon":24.6522}},{"facility":"Site 26","city":"Helsinki","zip":"00100","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"facility":"Site 27","city":"Helsinki","zip":"00930","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"facility":"Site 33","city":"Jarvenpaa","zip":"04400","country":"Finland","geoPoint":{"lat":60.47369,"lon":25.08992}},{"facility":"Site 35","city":"Kokkola","zip":"67100","country":"Finland","geoPoint":{"lat":63.83847,"lon":23.13066}},{"facility":"Site 34","city":"Kotka","zip":"48600","country":"Finland","geoPoint":{"lat":60.4664,"lon":26.94582}},{"facility":"Site 30","city":"Kuopio","zip":"70100","country":"Finland","geoPoint":{"lat":62.89238,"lon":27.67703}},{"facility":"Site 22","city":"Lahti","zip":"15140","country":"Finland","geoPoint":{"lat":60.98267,"lon":25.66151}},{"facility":"Site 31","city":"Oulu","zip":"90100","country":"Finland","geoPoint":{"lat":65.01236,"lon":25.46816}},{"facility":"Site 23","city":"Pori","zip":"28120","country":"Finland","geoPoint":{"lat":61.48072,"lon":21.78518}},{"facility":"Site 32","city":"Seinäjoki","zip":"60100","country":"Finland","geoPoint":{"lat":62.79446,"lon":22.82822}},{"facility":"Site 21","city":"Tampere","zip":"33100","country":"Finland","geoPoint":{"lat":61.49911,"lon":23.78712}},{"facility":"Site 24","city":"Turku","zip":"20520","country":"Finland","geoPoint":{"lat":60.45148,"lon":22.26869}},{"facility":"Site 28","city":"Vantaa","zip":"01300","country":"Finland","geoPoint":{"lat":60.29414,"lon":25.04099}},{"facility":"Site 29","city":"Vantaa","zip":"01600","country":"Finland","geoPoint":{"lat":60.29414,"lon":25.04099}},{"facility":"Site 49","city":"Bydgoszcz","zip":"85-316","country":"Poland","geoPoint":{"lat":53.1235,"lon":18.00762}},{"facility":"Site 62","city":"Gmina Końskie","zip":"26-200","country":"Poland","geoPoint":{"lat":51.19166,"lon":20.40607}},{"facility":"Site 53","city":"Gniewkowo","zip":"88-140","country":"Poland","geoPoint":{"lat":52.89461,"lon":18.40785}},{"facility":"Site 59","city":"Katowice","zip":"40-084","country":"Poland","geoPoint":{"lat":50.2597,"lon":19.02173}},{"facility":"Site 63","city":"Kielce","zip":"25-711","country":"Poland","geoPoint":{"lat":50.87033,"lon":20.62752}},{"facility":"Site 57","city":"Krakow","zip":"30-510","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Site 41","city":"Krakow","zip":"30-969","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Site 43","city":"Krakow","zip":"31-115","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Site 42","city":"Krakow","zip":"31-503","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Site 50","city":"Krakow","zip":"31-832","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Site 44","city":"Lubartów","zip":"21 - 100","country":"Poland","geoPoint":{"lat":51.46026,"lon":22.60952}},{"facility":"Site 45","city":"Lublin","zip":"20-044","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"Site 65","city":"Oleśnica","zip":"56-400","country":"Poland","geoPoint":{"lat":51.21338,"lon":17.38986}},{"facility":"Site 47","city":"Olsztyn","zip":"10-117","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"facility":"Site 48","city":"Olsztyn","zip":"10-295","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"facility":"Site 46","city":"Olsztyn","zip":"10-461","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"facility":"Site 58","city":"Radziszów","zip":"32-052","country":"Poland","geoPoint":{"lat":49.93531,"lon":19.81522}},{"facility":"Site 61","city":"Ruda Śląska","zip":"41-703","country":"Poland","geoPoint":{"lat":50.2584,"lon":18.85632}},{"facility":"Site 60","city":"Rzeszów","zip":"35-324","country":"Poland","geoPoint":{"lat":50.04132,"lon":21.99901}},{"facility":"Site 52","city":"Warsaw","zip":"02-777","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Site 54","city":"Wąbrzeźno","zip":"87-200","country":"Poland","geoPoint":{"lat":53.27989,"lon":18.94773}},{"facility":"Site 55","city":"Wilkowice","zip":"43-365","country":"Poland","geoPoint":{"lat":49.76282,"lon":19.08973}},{"facility":"Site 64","city":"Wroclaw","zip":"51-312","country":"Poland","geoPoint":{"lat":51.10286,"lon":17.03006}},{"facility":"Site 51","city":"Łodź","zip":"90-302","country":"Poland"}]},"referencesModule":{"references":[{"pmid":"20868284","type":"RESULT","citation":"Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, Holmes S. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis. 2010 Nov 1;51(9):997-1004. doi: 10.1086/656578."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"All enrolled subjects were included in the trial.","recruitmentDetails":"Participants were enrolled at multiple centres in the US, Poland and Finland.","groups":[{"id":"FG000","title":"CCI Vaccine","description":"One dose of cell culture-derived influenza vaccine."},{"id":"FG001","title":"IVV Vaccine","description":"One dose of the trivalent egg-derived influenza virus vaccine."},{"id":"FG002","title":"Placebo","description":"One dose of phosphate buffered solution (PBS)."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"3828"},{"groupId":"FG001","numSubjects":"3676"},{"groupId":"FG002","numSubjects":"3900"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3622"},{"groupId":"FG001","numSubjects":"3510"},{"groupId":"FG002","numSubjects":"3712"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"206"},{"groupId":"FG001","numSubjects":"166"},{"groupId":"FG002","numSubjects":"188"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"5"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"175"},{"groupId":"FG001","numSubjects":"143"},{"groupId":"FG002","numSubjects":"170"}]},{"type":"Inappropriate enrollment","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"3"}]},{"type":"Unable to classify","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"3"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"6"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"CCI Vaccine","description":"One dose of cell culture-derived influenza vaccine."},{"id":"BG001","title":"IVV Vaccine","description":"One dose of the trivalent egg-derived influenza virus vaccine."},{"id":"BG002","title":"Placebo","description":"One dose of phosphate buffered solution (PBS)."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"3828"},{"groupId":"BG001","value":"3676"},{"groupId":"BG002","value":"3900"},{"groupId":"BG003","value":"11404"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"32.7","spread":"10.1"},{"groupId":"BG001","value":"33.0","spread":"10.2"},{"groupId":"BG002","value":"32.7","spread":"10.2"},{"groupId":"BG003","value":"32.8","spread":"10.2"}]}]}]},{"title":"Sex/Gender, Customized","description":"Baseline Characteristics are reported for the Enrolled Population. For 3 of 11404 subjects, data on gender was not reported. Therefore, these data are not available.","paramType":"NUMBER","unitOfMeasure":"Subjects","classes":[{"title":"Female","categories":[{"measurements":[{"groupId":"BG000","value":"2088"},{"groupId":"BG001","value":"2026"},{"groupId":"BG002","value":"2176"},{"groupId":"BG003","value":"6290"}]}]},{"title":"Male","categories":[{"measurements":[{"groupId":"BG000","value":"1740"},{"groupId":"BG001","value":"1649"},{"groupId":"BG002","value":"1722"},{"groupId":"BG003","value":"5111"}]}]},{"title":"Not Available","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"3"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Culture-Confirmed Influenza Illness Caused by Vaccine-like Strains","description":"The vaccine efficacy of CCI and IVV vaccines was estimated relative to Placebo group as the number of subjects prevented against virus-confirmed symptomatic influenza illness caused by each of three vaccine-like virus strains.","populationDescription":"Analysis was performed on per protocol (PP) efficacy population i.e. the subjects in the exposed efficacy population who correctly received the vaccine and provided evaluable swab samples at the relevant time points.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"6 Months","groups":[{"id":"OG000","title":"CCI Vaccine","description":"One dose of cell culture-derived influenza vaccine."},{"id":"OG001","title":"IVV Vaccine","description":"One dose of the trivalent egg-derived influenza virus vaccine."},{"id":"OG002","title":"Placebo","description":"One dose of phosphate buffered solution (PBS)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3776"},{"groupId":"OG001","value":"3638"},{"groupId":"OG002","value":"3843"}]}],"classes":[{"title":"Overall","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"44"}]}]},{"title":"A/Wisconsin/67/2005 (H3N2)-like","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]},{"title":"A/Solomon Islands/3/2006 (H1N1)-like","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"43"}]}]},{"title":"B/Malaysia/2506/2004-like","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Vaccine efficacy (VE) of CCI vaccine vs. Placebo (Overall)\n\nSimultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.001","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","paramType":"Vaccine Efficacy","paramValue":"83.8","ciPctValue":"97.5","ciNumSides":"ONE_SIDED","ciLowerLimit":"61.0"},{"groupIds":["OG000","OG002"],"groupDescription":"Vaccine efficacy (VE) of CCI vaccine vs. Placebo for A/H1N1 strain\n\nSimultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.001","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","paramType":"Vaccine Efficacy","paramValue":"88.2","ciPctValue":"97.5","ciNumSides":"ONE_SIDED","ciLowerLimit":"67.4"},{"groupIds":["OG000","OG002"],"groupDescription":"Vaccine efficacy (VE) of CCI vaccine vs. Placebo for A/H3N2 strain. Simultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.999","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","statisticalComment":"For strain A/H3N2, the vaccine efficacy of the CCI vaccine vs. placebo was not evaluable since no influenza case was observed in the placebo group.","ciPctValue":"97.5"},{"groupIds":["OG000","OG002"],"groupDescription":"Vaccine efficacy (VE) of CCI vaccine vs. Placebo for B strain\n\nSimultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.394","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","paramType":"Vaccine Efficacy","paramValue":"100","ciPctValue":"97.5","ciNumSides":"ONE_SIDED","ciLowerLimit":"-410"},{"groupIds":["OG001","OG002"],"groupDescription":"Vaccine efficacy (VE) of IVV vaccine vs. Placebo (Overall)\n\nSimultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.004","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","paramType":"Vaccine Efficacy","paramValue":"78.4","ciPctValue":"97.5","ciNumSides":"ONE_SIDED","ciLowerLimit":"52.1"},{"groupIds":["OG001","OG002"],"groupDescription":"Vaccine efficacy (VE) of IVV vaccine vs. Placebo for A/H1N1 strain\n\nSimultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.002","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","paramType":"Vaccine Efficacy","paramValue":"80.3","ciPctValue":"97.5","ciNumSides":"ONE_SIDED","ciLowerLimit":"54.7"},{"groupIds":["OG001","OG002"],"groupDescription":"Vaccine efficacy (VE) of IVV vaccine vs. Placebo for A/H3N2 strain. Simultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.992","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","statisticalComment":"For strain A/H3N2, the vaccine efficacy of the IVV vaccine vs. placebo was not evaluable since no influenza case was observed in the placebo group.","ciPctValue":"97.5"},{"groupIds":["OG001","OG002"],"groupDescription":"Vaccine efficacy (VE) of IVV vaccine vs. Placebo for B strain\n\nSimultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.400","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","paramType":"Vaccine Efficacy","paramValue":"100","ciPctValue":"97.5","ciNumSides":"ONE_SIDED","ciLowerLimit":"-429.4"}]},{"type":"SECONDARY","title":"Number of Subjects With Culture-confirmed Influenza Illness Caused by Non-Vaccine Like Strains","description":"The vaccine efficacy of CCI and IVV vaccines was estimated relative to placebo group as the number of subjects prevented against virus-confirmed symptomatic influenza A or B illness caused by non-vaccine-like strains.","populationDescription":"Analysis was done on PP efficacy population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"6 Months","groups":[{"id":"OG000","title":"CCI Vaccine","description":"One dose of cell culture-derived influenza vaccine."},{"id":"OG001","title":"IVV Vaccine","description":"One dose of the trivalent egg-derived influenza virus vaccine."},{"id":"OG002","title":"Placebo","description":"One dose of phosphate buffered solution (PBS)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3776"},{"groupId":"OG001","value":"3638"},{"groupId":"OG002","value":"3843"}]}],"classes":[{"title":"Overall","categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"74"}]}]},{"title":"A/H3N2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"8"}]}]},{"title":"A/H1N1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"8"}]}]},{"title":"B","categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"59"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Vaccine efficacy (VE) of CCI vaccine vs. Placebo (Overall)\n\nSimultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.078","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","paramType":"Vaccine Efficacy","paramValue":"58.7","ciPctValue":"97.5","ciNumSides":"ONE_SIDED","ciLowerLimit":"33.5"},{"groupIds":["OG000","OG002"],"groupDescription":"Vaccine efficacy (VE) of CCI vaccine vs. Placebo for A/H1N1 strain\n\nSimultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.104","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","paramType":"Vaccine Efficacy","paramValue":"87.3","ciPctValue":"97.5","ciNumSides":"ONE_SIDED","ciLowerLimit":"4.6"},{"groupIds":["OG000","OG002"],"groupDescription":"Vaccine efficacy (VE) of CCI vaccine vs. Placebo for A/H3N2 strain\n\nSimultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.030","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","paramType":"Vaccine Efficacy","paramValue":"100","ciPctValue":"97.5","ciNumSides":"ONE_SIDED","ciLowerLimit":"36.3"},{"groupIds":["OG000","OG002"],"groupDescription":"Vaccine efficacy (VE) of CCI vaccine vs. Placebo for B strain\n\nSimultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.376","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","paramType":"Vaccine Efficacy","paramValue":"50.0","ciPctValue":"97.5","ciNumSides":"ONE_SIDED","ciLowerLimit":"17.5"},{"groupIds":["OG001","OG002"],"groupDescription":"Vaccine efficacy (VE) of IVV vaccine vs. Placebo (Overall)\n\nSimultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.085","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","paramType":"Vaccine Efficacy","paramValue":"58.6","ciPctValue":"97.5","ciNumSides":"ONE_SIDED","ciLowerLimit":"32.9"},{"groupIds":["OG001","OG002"],"groupDescription":"Vaccine efficacy (VE) of IVV vaccine vs. Placebo for A/H1N1 strain\n\nSimultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.033","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","paramType":"Vaccine Efficacy","paramValue":"100","ciPctValue":"97.5","ciNumSides":"ONE_SIDED","ciLowerLimit":"33.9"},{"groupIds":["OG001","OG002"],"groupDescription":"Vaccine efficacy (VE) of IVV vaccine vs. Placebo for A/H3N2 strain\n\nSimultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.265","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","paramType":"Vaccine Efficacy","paramValue":"73.6","ciPctValue":"97.5","ciNumSides":"ONE_SIDED","ciLowerLimit":"-30.0"},{"groupIds":["OG001","OG002"],"groupDescription":"Vaccine efficacy (VE) of IVV vaccine vs. Placebo for B strain\n\nSimultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.319","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","paramType":"Vaccine Efficacy","paramValue":"51.7","ciPctValue":"97.5","ciNumSides":"ONE_SIDED","ciLowerLimit":"19.4"}]},{"type":"SECONDARY","title":"Number of Subjects With Influenza Caused by Vaccine-like and Non-vaccine-like Strains","description":"The vaccine efficacy of CCI and IVV vaccines was estimated relative to placebo as the number of subjected prevented against virus-confirmed symptomatic influenza A or B illness caused by vaccine-like and non-vaccine-like strains.","populationDescription":"Analysis was done on PP efficacy population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"6 Months","groups":[{"id":"OG000","title":"CCI Vaccine","description":"One dose of cell culture-derived influenza vaccine."},{"id":"OG001","title":"IVV Vaccine","description":"One dose of the trivalent egg-derived influenza virus vaccine."},{"id":"OG002","title":"Placebo","description":"One dose of phosphate buffered solution (PBS)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3776"},{"groupId":"OG001","value":"3638"},{"groupId":"OG002","value":"3843"}]}],"classes":[{"title":"Overall","categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"140"}]}]},{"title":"A/H3N2","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"25"}]}]},{"title":"A/H1N1","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"57"}]}]},{"title":"B","categories":[{"measurements":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"61"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"groupDescription":"Vaccine efficacy (VE) of CCI vaccine vs. Placebo (Overall)\n\nSimultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.001","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","paramType":"Vaccine Efficacy","paramValue":"69.5","ciPctValue":"97.5","ciNumSides":"ONE_SIDED","ciLowerLimit":"55.0"},{"groupIds":["OG000","OG002"],"groupDescription":"Vaccine efficacy (VE) of CCI vaccine vs. Placebo for A/H1N1 strain\n\nSimultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.001","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","paramType":"Vaccine Efficacy","paramValue":"89.3","ciPctValue":"97.5","ciNumSides":"ONE_SIDED","ciLowerLimit":"73.0"},{"groupIds":["OG000","OG002"],"groupDescription":"Vaccine efficacy (VE) of CCI vaccine vs. Placebo for A/H3N2 strain\n\nSimultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.040","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","paramType":"Vaccine Efficacy","paramValue":"75.6","ciPctValue":"97.5","ciNumSides":"ONE_SIDED","ciLowerLimit":"35.1"},{"groupIds":["OG000","OG002"],"groupDescription":"Vaccine efficacy (VE) of CCI vaccine vs. Placebo for B strain\n\nSimultaneous one-sided 97.5% confidence interval (CI) for the VE of CCI vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.37","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of CCI vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","paramType":"Vaccine Efficacy","paramValue":"49.9","ciPctValue":"97.5","ciNumSides":"ONE_SIDED","ciLowerLimit":"18.2"},{"groupIds":["OG001","OG002"],"groupDescription":"Vaccine efficacy (VE) of IVV vaccine vs. Placebo (Overall)\n\nSimultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.003","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","paramType":"Vaccine Efficacy","paramValue":"63.0","ciPctValue":"97.5","ciNumSides":"ONE_SIDED","ciLowerLimit":"46.7"},{"groupIds":["OG001","OG002"],"groupDescription":"Vaccine efficacy (VE) of IVV vaccine vs. Placebo for A/H1N1 strain\n\nSimultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.001","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","paramType":"Vaccine Efficacy","paramValue":"81.5","ciPctValue":"97.5","ciNumSides":"ONE_SIDED","ciLowerLimit":"60.9"},{"groupIds":["OG001","OG002"],"groupDescription":"Vaccine efficacy (VE) of IVV vaccine vs. Placebo for A/H3N2 strain\n\nSimultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.53","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","paramType":"Vaccine Efficacy","paramValue":"49.3","ciPctValue":"97.5","ciNumSides":"ONE_SIDED","ciLowerLimit":"-9.0"},{"groupIds":["OG001","OG002"],"groupDescription":"Vaccine efficacy (VE) of IVV vaccine vs. Placebo for B strain\n\nSimultaneous one-sided 97.5% confidence interval (CI) for the VE of IVV vaccine relative to Placebo was based on the Sidak-corrected score CIs for the two relative risks.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.26","pValueComment":"Adjusted p-values are from score statistic with Sidak correction testing the null hypothesis that the VE of IVV vs. placebo is \\<= 40% (the relative risk, \\>= 0.60). If adjusted p-value is \\<0.025, then the comparison is statistically significant.","statisticalMethod":"Sidak-corrected score CI","paramType":"Vaccine Efficacy","paramValue":"53.2","ciPctValue":"97.5","ciNumSides":"ONE_SIDED","ciLowerLimit":"22.2"}]},{"type":"SECONDARY","title":"Influenza-Associated Days in Bed, All Subjects","description":"The number of subjects in this analysis included all subjects in the per protocol efficacy population.","populationDescription":"Analysis was done on the PP efficacy population.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Number of Days","timeFrame":"6 Months","groups":[{"id":"OG000","title":"CCI Vaccine","description":"One dose of cell culture-derived influenza vaccine."},{"id":"OG001","title":"IVV Vaccine","description":"One dose of the trivalent egg-derived influenza virus vaccine."},{"id":"OG002","title":"Placebo","description":"One dose of phosphate buffered solution (PBS)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3775"},{"groupId":"OG001","value":"3638"},{"groupId":"OG002","value":"3837"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.496"},{"groupId":"OG001","value":"0.04","spread":"0.404"},{"groupId":"OG002","value":"0.12","spread":"0.777"}]}]}]},{"type":"SECONDARY","title":"Influenza-Associated Days in Bed, Subset of Subjects With Virus-Confirmed- Influenza","description":"The analysis was done among the subset of subjects in the per protocol efficacy population who had culture-confirmed influenza.","populationDescription":"Analysis was done on PP efficacy population.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Number of Days","timeFrame":"6 Months","groups":[{"id":"OG000","title":"CCI Vaccine","description":"One dose of cell culture-derived influenza vaccine."},{"id":"OG001","title":"IVV Vaccine","description":"One dose of the trivalent egg-derived influenza virus vaccine."},{"id":"OG002","title":"Placebo","description":"One dose of phosphate buffered solution (PBS)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"230"},{"groupId":"OG002","value":"332"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"2.62"},{"groupId":"OG001","value":"2.9","spread":"1.98"},{"groupId":"OG002","value":"3.4","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Number Of Medical Visits (Inpatient and Outpatient) Due to Influenza Illness or Symptoms of Influenza, All Subjects","description":"The number of subjects in this analysis included all subjects in the per protocol efficacy population.","populationDescription":"Analysis was done of PP efficacy population.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Number of Medical Visits","timeFrame":"6 Months","groups":[{"id":"OG000","title":"CCI Vaccine","description":"One dose of cell culture-derived influenza vaccine."},{"id":"OG001","title":"IVV Vaccine","description":"One dose of the trivalent egg-derived influenza virus vaccine."},{"id":"OG002","title":"Placebo","description":"One dose of phosphate buffered solution (PBS)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3775"},{"groupId":"OG001","value":"3638"},{"groupId":"OG002","value":"3838"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.138"},{"groupId":"OG001","value":"0.01","spread":"0.134"},{"groupId":"OG002","value":"0.03","spread":"0.262"}]}]}]},{"type":"SECONDARY","title":"Number of Medical Visits (Inpatient and Outpatient), Subset of Subjects With Virus-Confirmed-Influenza","description":"The analysis was done among the subset of subjects in the per protocol efficacy population who had culture-confirmed influenza.","populationDescription":"Analysis was done of PP efficacy population.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Number of Medical Visits","timeFrame":"6 Months","groups":[{"id":"OG000","title":"CCI Vaccine","description":"One dose of cell culture-derived influenza vaccine."},{"id":"OG001","title":"IVV Vaccine","description":"One dose of the trivalent egg-derived influenza virus vaccine."},{"id":"OG002","title":"Placebo","description":"One dose of phosphate buffered solution (PBS)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"230"},{"groupId":"OG002","value":"332"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.92"},{"groupId":"OG001","value":"0.6","spread":"1.0"},{"groupId":"OG002","value":"0.8","spread":"1.16"}]}]}]},{"type":"SECONDARY","title":"Number of Days of Usual Activity (i.e. Job, School,Household/Family/Community Activities) Lost Due to Influenza Disease, All Subjects","description":"The number of subjects in this analysis included all subjects in the per protocol efficacy population.","populationDescription":"Analysis was done on PP efficacy population.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Numebr of Days of Usual Activity Lost","timeFrame":"6 Months","groups":[{"id":"OG000","title":"CCI Vaccine","description":"One dose of cell culture-derived influenza vaccine."},{"id":"OG001","title":"IVV Vaccine","description":"One dose of the trivalent egg-derived influenza virus vaccine."},{"id":"OG002","title":"Placebo","description":"One dose of phosphate buffered solution (PBS)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3775"},{"groupId":"OG001","value":"3638"},{"groupId":"OG002","value":"3837"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.635"},{"groupId":"OG001","value":"0.05","spread":"0.605"},{"groupId":"OG002","value":"0.16","spread":"1.006"}]}]}]},{"type":"SECONDARY","title":"Number of Days of Usual Activity (i.e. Job, School,Household/Family/Community Activities) Lost, Subset of Subjects With Virus-Confirmed-Influenza","description":"The analysis was done among the subset of subjects in the per protocol efficacy population who had culture-confirmed influenza.","populationDescription":"Analysis was done on PP efficacy population.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Numebr of Days of Usual Activity Lost","timeFrame":"6 Months","groups":[{"id":"OG000","title":"CCI Vaccine","description":"One dose of cell culture-derived influenza vaccine."},{"id":"OG001","title":"IVV Vaccine","description":"One dose of the trivalent egg-derived influenza virus vaccine."},{"id":"OG002","title":"Placebo","description":"One dose of phosphate buffered solution (PBS)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"230"},{"groupId":"OG002","value":"332"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"3.41"},{"groupId":"OG001","value":"4.0","spread":"3.4"},{"groupId":"OG002","value":"4.6","spread":"3.45"}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects Who Achieved HI Titers ≥40 After One Vaccination of Either Cell-culture Derived or Egg-derived Influenza Vaccine or Placebo","description":"Immunogenicity was measured as the percentage of subjects achieving HI titers ≥40 at baseline (day 1) and three weeks after (day 22) one vaccination of either cell-culture or egg-derived vaccine or placebo for each of the three influenza vaccine strains (A/H1N1, A/H3N2 and B), evaluated using hemagglutination inhibition (HI) egg-derived antigen assay. This criterion is met according to US (CBER) guideline if the lower limit of the two-sided 95% CI for the percentage of subjects achieving HI titers ≥40 is ≥70%.","populationDescription":"Analysis was done on a subset of subjects who constituted the PP immunogenicity population.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentages of subjects","timeFrame":"Before vaccination (day 1) and three weeks after vaccination (day 22)","groups":[{"id":"OG000","title":"CCI Vaccine","description":"One dose of cell culture-derived influenza vaccine."},{"id":"OG001","title":"IVV Vaccine","description":"One dose of the trivalent egg-derived influenza virus vaccine."},{"id":"OG002","title":"Placebo","description":"One dose of phosphate buffered solution (PBS)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"228"},{"groupId":"OG001","value":"695"},{"groupId":"OG002","value":"55"}]}],"classes":[{"title":"A/H1N1 - Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"48","lowerLimit":"42","upperLimit":"55"},{"groupId":"OG001","value":"53","lowerLimit":"49","upperLimit":"57"},{"groupId":"OG002","value":"60","lowerLimit":"46","upperLimit":"73"}]}]},{"title":"A/H1N1 - Day 22","categories":[{"measurements":[{"groupId":"OG000","value":"99","lowerLimit":"97","upperLimit":"100"},{"groupId":"OG001","value":"98","lowerLimit":"97","upperLimit":"99"},{"groupId":"OG002","value":"60","lowerLimit":"46","upperLimit":"73"}]}]},{"title":"A/H3N2 - Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"63","lowerLimit":"57","upperLimit":"69"},{"groupId":"OG001","value":"58","lowerLimit":"54","upperLimit":"61"},{"groupId":"OG002","value":"71","lowerLimit":"57","upperLimit":"82"}]}]},{"title":"A/H3N2 - Day 22","categories":[{"measurements":[{"groupId":"OG000","value":"99","lowerLimit":"97","upperLimit":"100"},{"groupId":"OG001","value":"99","lowerLimit":"98","upperLimit":"100"},{"groupId":"OG002","value":"65","lowerLimit":"51","upperLimit":"78"}]}]},{"title":"B - Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"25","lowerLimit":"20","upperLimit":"31"},{"groupId":"OG001","value":"23","lowerLimit":"20","upperLimit":"27"},{"groupId":"OG002","value":"22","lowerLimit":"12","upperLimit":"35"}]}]},{"title":"B - Day 22","categories":[{"measurements":[{"groupId":"OG000","value":"78","lowerLimit":"72","upperLimit":"83"},{"groupId":"OG001","value":"92","lowerLimit":"90","upperLimit":"94"},{"groupId":"OG002","value":"22","lowerLimit":"12","upperLimit":"35"}]}]}]},{"type":"SECONDARY","title":"Percentages of Subjects Achieving Seroconversion After One Vaccination of Either Cell-culture Derived or Egg-derived Influenza Vaccine or Placebo","description":"As per the CBER guideline, seroconversion is defined as the percentage of subjects with a prevaccination HI titer \\<10, a postvaccination titer ≥40; or in subjects with prevaccination HI titer ≥10, a ≥4-fold increase in postvaccination HI antibody titer. According to CBER criteria, the lower limit of the two-sided 95% CI for the percentage of subjects achieving seroconversion for HI antibody titer at day 22 met exceeded 40%.","populationDescription":"Analysis was done on a subset of subjects who constituted the PP immunogenicity population.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentages of subjects","timeFrame":"Three weeks after vaccination (day 22)","groups":[{"id":"OG000","title":"CCI Vaccine","description":"One dose of cell culture-derived influenza vaccine."},{"id":"OG001","title":"IVV Vaccine","description":"One dose of the trivalent egg-derived influenza virus vaccine."},{"id":"OG002","title":"Placebo","description":"One dose of phosphate buffered solution (PBS)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"228"},{"groupId":"OG001","value":"695"},{"groupId":"OG002","value":"55"}]}],"classes":[{"title":"A/H1N1","categories":[{"measurements":[{"groupId":"OG000","value":"78","lowerLimit":"72","upperLimit":"83"},{"groupId":"OG001","value":"75","lowerLimit":"71","upperLimit":"78"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"6"}]}]},{"title":"A/H3N2","categories":[{"measurements":[{"groupId":"OG000","value":"59","lowerLimit":"53","upperLimit":"66"},{"groupId":"OG001","value":"68","lowerLimit":"64","upperLimit":"71"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"6"}]}]},{"title":"B","categories":[{"measurements":[{"groupId":"OG000","value":"51","lowerLimit":"45","upperLimit":"58"},{"groupId":"OG001","value":"68","lowerLimit":"65","upperLimit":"72"},{"groupId":"OG002","value":"0","lowerLimit":"0","upperLimit":"6"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Reported Solicited Local and Systemic Reactions up to 7 Days After Vaccination","description":"The solicited local and systemic reactogenicity were collected up to 7 days after vaccination for all three vaccine groups.","populationDescription":"Analysis was done on Safety population i.e. all subjects in the exposed population who provide post vaccination safety data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Subjects","timeFrame":"Up to 7 days post vaccination","groups":[{"id":"OG000","title":"CCI Vaccine","description":"One dose of cell culture-derived influenza vaccine."},{"id":"OG001","title":"IVV Vaccine","description":"One dose of the trivalent egg-derived influenza virus vaccine."},{"id":"OG002","title":"Placebo","description":"One dose of phosphate buffered solution (PBS)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3813"},{"groupId":"OG001","value":"3669"},{"groupId":"OG002","value":"3894"}]}],"classes":[{"title":"Injection site Pain","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3813"},{"groupId":"OG001","value":"3668"},{"groupId":"OG002","value":"3894"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1158"},{"groupId":"OG001","value":"893"},{"groupId":"OG002","value":"375"}]}]},{"title":"Injection site Erythema","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3813"},{"groupId":"OG001","value":"3668"},{"groupId":"OG002","value":"3894"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"510"},{"groupId":"OG001","value":"492"},{"groupId":"OG002","value":"391"}]}]},{"title":"Injection site Induration","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3813"},{"groupId":"OG001","value":"3668"},{"groupId":"OG002","value":"3894"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"239"},{"groupId":"OG001","value":"207"},{"groupId":"OG002","value":"101"}]}]},{"title":"Injection site Ecchymosis","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3813"},{"groupId":"OG001","value":"3668"},{"groupId":"OG002","value":"3894"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"110"},{"groupId":"OG002","value":"147"}]}]},{"title":"Injection site Swelling","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3813"},{"groupId":"OG001","value":"3667"},{"groupId":"OG002","value":"3894"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"181"},{"groupId":"OG002","value":"103"}]}]},{"title":"Chills","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3813"},{"groupId":"OG001","value":"3669"},{"groupId":"OG002","value":"3894"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"210"},{"groupId":"OG001","value":"211"},{"groupId":"OG002","value":"223"}]}]},{"title":"Malaise","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3813"},{"groupId":"OG001","value":"3669"},{"groupId":"OG002","value":"3893"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"290"},{"groupId":"OG001","value":"259"},{"groupId":"OG002","value":"237"}]}]},{"title":"Myalgia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3813"},{"groupId":"OG001","value":"3669"},{"groupId":"OG002","value":"3893"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"450"},{"groupId":"OG001","value":"364"},{"groupId":"OG002","value":"275"}]}]},{"title":"Arthralgia","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3813"},{"groupId":"OG001","value":"3669"},{"groupId":"OG002","value":"3893"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"111"},{"groupId":"OG002","value":"125"}]}]},{"title":"Headache","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3813"},{"groupId":"OG001","value":"3669"},{"groupId":"OG002","value":"3893"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"564"},{"groupId":"OG001","value":"551"},{"groupId":"OG002","value":"592"}]}]},{"title":"Sweating","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3812"},{"groupId":"OG001","value":"3669"},{"groupId":"OG002","value":"3893"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"122"},{"groupId":"OG002","value":"120"}]}]},{"title":"Fatigue","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3812"},{"groupId":"OG001","value":"3669"},{"groupId":"OG002","value":"3893"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"390"},{"groupId":"OG001","value":"404"},{"groupId":"OG002","value":"384"}]}]},{"title":"Fever (>= 38 C)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3813"},{"groupId":"OG001","value":"3669"},{"groupId":"OG002","value":"3894"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"15"}]}]},{"title":"Oral Temp. (< 38 C)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3813"},{"groupId":"OG001","value":"3669"},{"groupId":"OG002","value":"3894"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3786"},{"groupId":"OG001","value":"3648"},{"groupId":"OG002","value":"3879"}]}]},{"title":"Stayed home due to Reactions (N=3781, 3651, 3867)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3781"},{"groupId":"OG001","value":"3651"},{"groupId":"OG002","value":"3867"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"62"},{"groupId":"OG002","value":"42"}]}]},{"title":"Analgesic medicines used","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3810"},{"groupId":"OG001","value":"3665"},{"groupId":"OG002","value":"3892"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"394"},{"groupId":"OG001","value":"397"},{"groupId":"OG002","value":"386"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Serious Adverse Events were collected throughout the study period (i.e., 6 months).","description":"The analysis was done on the safety population.","eventGroups":[{"id":"EG000","title":"CCI Vaccine","description":"One dose of cell culture-derived influenza vaccine.","seriousNumAffected":42,"seriousNumAtRisk":3813,"otherNumAffected":1949,"otherNumAtRisk":3813},{"id":"EG001","title":"IVV Vaccine","description":"One dose of the trivalent egg-derived influenza virus vaccine.","seriousNumAffected":35,"seriousNumAtRisk":3669,"otherNumAffected":1703,"otherNumAtRisk":3669},{"id":"EG002","title":"Placebo","description":"One dose of phosphate buffered solution (PBS).","seriousNumAffected":38,"seriousNumAtRisk":3894,"otherNumAffected":1387,"otherNumAtRisk":3894}],"seriousEvents":[{"term":"Cardiac Failure Congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Coronary Artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Vertigo Positional","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Mydriasis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Abdominal Pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Abdominal Pain Upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Anal Fistula","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Colitis Ischaemic","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Crohn's Disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Gastrooesophageal Reflux Disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Inguinal Hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Intestinal Obstructon","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Pancreatitis Acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Peritoneal Cyst","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Salivary Duct Inflammation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Salivary Gland Calculus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Small Intestinal Obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Vomiting in Pregnancy","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Chest Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Non-Cardiac Chest Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Cholangitis Sclerosing","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Cholecystitis Acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Hepatitis Acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Jaundice","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Acute Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Acute Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":3894}]},{"term":"Breast Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Gastroenteritis Viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Lung Abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Mastitis Bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Perirectal Abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Peritonsillar Abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":3894}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":3894}]},{"term":"Pyelonephritis Acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Wound Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Abdominal Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Alcohol Poisoning","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Ankle Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Chest Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Extradural Haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Foot Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Joint Injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Road Traffic Accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Skull Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Subdural Haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Tendon Rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Upper Limb Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Obesity","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Back Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":3894}]},{"term":"Intervertebral Disc Protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":3894}]},{"term":"Adenocarcinoma of the Cervix","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Bone Neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Breast Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Carcinoid Tumour","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Leiomyosarcoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Ovarian Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Cerebral Haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Loss of Consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Tethered Cord Syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Abortion Spontaneous","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Delivery","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Ectopic Pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Acute Stress Disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Bipolar Disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Borderline Personality Disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Major Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Psychotic Disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Bladder Prolapse","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Renal Failure Acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Breast Hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Dysmenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Haemorrhagic Ovarian Cyst","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Menometrorrhagia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Pelvic Pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Polycystic Ovaries","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Uterine Haemorrhage","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Nasal Septum Deviation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Pulmonary Embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Tonsillar Hypertrophy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Dermatitis Atopic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Homicide","organSystem":"Social circumstances","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Aortic Valve Replacement","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Appendicetomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]},{"term":"Knee Operation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Medical Device Removal","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Nasal Septal Operation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Rhinoplasty","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Tendon Operation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Deep Vein Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Thrombophlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":3669},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3894}]},{"term":"Varicose Vein","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":3813},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":3669},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3894}]}],"otherEvents":[{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":212,"numAtRisk":3813},{"groupId":"EG001","numAffected":212,"numAtRisk":3669},{"groupId":"EG002","numAffected":225,"numAtRisk":3894}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":390,"numAtRisk":3813},{"groupId":"EG001","numAffected":404,"numAtRisk":3669},{"groupId":"EG002","numAffected":386,"numAtRisk":3894}]},{"term":"Injection Site Erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":510,"numAtRisk":3813},{"groupId":"EG001","numAffected":492,"numAtRisk":3669},{"groupId":"EG002","numAffected":391,"numAtRisk":3894}]},{"term":"Injection Site Induration","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":239,"numAtRisk":3813},{"groupId":"EG001","numAffected":207,"numAtRisk":3669},{"groupId":"EG002","numAffected":101,"numAtRisk":3894}]},{"term":"Injection Site Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1158,"numAtRisk":3813},{"groupId":"EG001","numAffected":893,"numAtRisk":3669},{"groupId":"EG002","numAffected":375,"numAtRisk":3894}]},{"term":"Injection Site Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":218,"numAtRisk":3813},{"groupId":"EG001","numAffected":181,"numAtRisk":3669},{"groupId":"EG002","numAffected":103,"numAtRisk":3894}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":290,"numAtRisk":3813},{"groupId":"EG001","numAffected":260,"numAtRisk":3669},{"groupId":"EG002","numAffected":238,"numAtRisk":3894}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":451,"numAtRisk":3813},{"groupId":"EG001","numAffected":369,"numAtRisk":3669},{"groupId":"EG002","numAffected":278,"numAtRisk":3894}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":571,"numAtRisk":3813},{"groupId":"EG001","numAffected":554,"numAtRisk":3669},{"groupId":"EG002","numAffected":597,"numAtRisk":3894}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Posting Director","organization":"Novartis Vaccines and Diagnostics","email":"RegistryContactVaccinesUS@novartis.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D007251","term":"Influenza, Human"}],"ancestors":[{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D009976","term":"Orthomyxoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]}},"hasResults":true}